

Protocol for Neutralizing Antibody Screening Assay for HIV-1 in TZM-bl Cells (November 2018)

I. Introduction

This assay measures percent neutralization in TZM-bl cells as a function of a reduction in Tat-induced luciferase (Luc) reporter gene expression in the presence of post-immune samples relative to corresponding pre-immune samples after a single round of virus infection. TZM-bl cells (also called JC57BL-13) may be obtained from the NIH AIDS Reagent Program. This is a HeLa cell clone that was engineered to express CD4 and CCR5 [4.1] and contains integrated reporter genes for firefly luciferase and *E. coli* β -galactosidase under control of an HIV-1 LTR [4.2], permitting sensitive and accurate measurements of infection. The cells are highly permissive to infection by most strains of HIV, SIV and SHIV, including primary HIV-1 isolates and molecularly cloned Env-pseudotyped viruses. DEAE dextran is used in the medium during neutralization assays to enhance infectivity. Expression of the reporter genes is induced in trans by viral Tat protein soon after infection. Luciferase activity is quantified by luminescence and is directly proportional to the number of infectious virus particles present in the initial inoculum. The assay is performed in 96-well culture plates for high throughput capacity. Use of a clonal cell population provides enhanced precision and uniformity. The assay has been validated for single-round infection with either uncloned virus quasispecies or molecularly cloned Env-pseudotyped viruses [4.3].

Vaccine-elicited neutralizing antibody responses against tier 2 viruses tend to be very weak and detection can be missed despite the fact that these low titers could be important. For maximum sensitivity and specificity, post-immune samples can be screened at a single dilution, in triplicate, to measure the reduction in Relative Luminescence Units (RLU) relative to wells that contain the same dilution of the corresponding pre-immune samples. This way, neutralization is not measured relative to the virus control wells as is the case for the Neutralizing Antibody Assay for HIV-1 in TZM-bl cells where samples are assayed at multiple dilutions. Use of corresponding pre- and post-immune samples in the screening assay gives a more precise measure of true neutralization because it adjusts for non-specific effects. For example, values <50% neutralization in the screening assay may be significant if they exceed the positive deflection which may be seen in the placebo group. If there are no pre-immune samples available, samples can be screened where neutralization is measured relative to the virus control wells as is the case for the Neutralizing Antibody Assay for HIV-1 in TZM-bl cells.

II. Definitions

%CV: Percent coefficient of variation

DEAE-Dextran: Diethylaminoethyl-Dextran

DPBS: Dulbecco's Phosphate Buffered Saline

EDTA: Ethylenediaminetetraacetic acid

GM: Growth Medium

ID: Identification

Luc: Luciferase

NIH: National Institutes of Health

PI: Principal Investigator

RLU: Relative Luminescence Units

TCID: Tissue Culture Infectious Dose

Vol: Volume

III. Reagents and Materials

Recommended vendors are listed. Unless otherwise specified, products of equal or better quality than the recommended ones can be used whenever necessary.

TZM-bl Cells

Manufacturer: NIH AIDS Reagent Program

Complete Growth Medium (see Protocol for Reagent Preparation for Use in the Neutralizing Antibody Assay for HIV-1 in TZM-bl Cells)

DEAE-Dextran, hydrochloride, average Mol. Wt. 500,000 (see Protocol for Reagent Preparation for Use in the Neutralizing Antibody Assay for HIV-1 in TZM-bl Cells)

Manufacturer: Sigma

Trypsin-EDTA (0.25% trypsin, 1 mM EDTA) (see Protocol for Trypsin-EDTA Treatment for Disruption of Cell Monolayers)

Manufacturer: Invitrogen

Trypan Blue (0.4%)

Manufacturer: Thermo Fisher Scientific

Dulbecco's Phosphate Buffered Saline (DPBS)

Manufacturer: Thermo Fisher Scientific

Britelite Plus Reporter Gene Assay System (see Protocol for Reagent Preparation for Use in the Neutralizing Antibody Assay for HIV-1 in TZM-bl Cells)

Manufacturer: PerkinElmer

NOTE 1: The lyophilized britelite plus substrate is not classified as hazardous. Please follow manufacturer's guidelines for preparation and use.

Bright-Glo

Manufacturer: Promega

NOTE 2: Bright-Glo Luciferase Assay System from Promega Corporation is an acceptable substitute for britelite plus. Please follow manufacturer's guidelines for preparation and use. Bright-Glo is classified as

hazardous. Personal Protective Equipment (PPE) is required when working with this reagent.

Microliter pipettor tips, sterile

Manufacturer: Rainin or Sartorius

Disposable pipettes, sterile, individually wrapped

1 ml pipettes

2 ml pipettes

5 ml pipettes

10 ml pipettes

25 ml pipettes

50 ml pipettes

100 ml pipettes

Manufacturer: Corning

Flat-bottom culture plates, 96-well, low evaporation, sterile

Manufacturer: Corning

Flat-bottom black solid plates, 96-well

Manufacturer: PerkinElmer

Culture flasks with vented caps, sterile

T-25 flask

T-75 flask

Manufacturer: Corning

Reagent reservoirs, 50 ml, 100 ml capacity

Manufacturer: Corning

IV. Instrumentation

Recommended manufacturers are listed. Unless otherwise specified, equipment of equal or better quality than the recommended ones can be used whenever necessary.

Biological Safety Cabinet

Manufacturer: Baker Co.

Incubator (37°C, 5% CO₂ standard requirements)

Manufacturer: Panasonic

Centrifuge and Microcentrifuge

(low speed capable of up to 500 x g)

50 ml tube holder

15 ml tube holder

Microtitration plate holder

Manufacturer: Jouan

18 place standard rotor F-45-18-11 for 1.5 ml microcentrifuge tubes

Manufacturer: Eppendorf

Luminometer

Manufacturer: PerkinElmer

Water bath

Manufacturer: VWR International

Hemocytometer

Manufacturer: INCYTO

NOTE 3: An automated cell counting device (e.g., Countess, Manufacturer: Invitrogen) may be used in lieu of a light microscope / hemacytometer for cell counting and viability calculation.

Pipettor

Single channel electronic pipettor, 10-300 μ l

12-channel electronic pipettor, 50-1200 μ l

12-channel electronic pipettor, 10-300 μ l

Single channel manual, 0.5-10 μ l

Single channel manual, 2-20 μ l

Single channel manual, 20-200 μ l

Single channel manual, 100-1000 μ l

Manufacturer: Sartorius

PipetteAid XP

Manufacturer: Drummond Scientific Co.

12 channel pipettor, 20-200 μ l

Manufacturer: Rainin

Light Microscope

Manufacturer: Olympus

Ultra Low Temperature Freezer (-70°C or lower)

Manufacturer: Harris or Thermo Fisher Scientific

4 $^{\circ}$ C Refrigerator

Manufacturer: LABREPCO, Inc.

-20°C Freezer

Manufacturer: LABREPCO, Inc.

V. Specimens

Samples should be heat-inactivated at 56°C as described in Protocol for Heat-Inactivation of Serum and Plasma Samples. Samples may be serum or plasma, although serum is preferred. Anticoagulants in plasma are problematic in the assay, especially when heparin is used. For example, some forms of heparin have potent and strain-specific antiviral activity. All anticoagulants are toxic to the cells at low plasma dilutions.

VI. Protocol

1. Screening Neutralization Assay

NOTE 4: All incubations are performed in a humidified 37°C, 5% CO₂ incubator unless otherwise specified.

NOTE 5: The exterior-most wells in rows A and H are not utilized for the assay but serve as media blank (MB) wells. The entire column 12 also serves as media blank wells (see Appendices A, B, and C).

- 1.1 Using the format of a 96-well flat bottom culture plate as illustrated in Appendix A, B or C, place 150 µl of GM in all wells of B1-G1 of column 1 (cell control). Place 100 µl in wells B2-G2 of column 2 (virus control). Place an additional 85 µl in all wells of columns 3-11, rows B-G (to receive test samples). Place 200-250 µl in rows A and H and column 12 to serve as the media blank wells.

NOTE 6: Appendix A is designed to assay 9 samples per plate, each with 1 pre and 1 post bleed in triplicate wells. Appendix B is designed to assay 6 samples per plate, each with 1 pre and 2 post bleeds in triplicate wells. When pre-bleed samples are not available use Appendix C to assay 18 samples per plate.

- 1.2 Centrifuge the test samples at the appropriate time and speed in order to pellet any debris that might be present.
- 1.3 Add 15 µl of test sample in triplicate beginning in Row G, according to the plate layout described in Appendix A, B or C.

NOTE 7: The above description is for testing samples at a 1:10 dilution. Volume adjustments can be made to test a different dilution (Appendix D).

- 1.4 A positive control with a known neutralization titer against the target virus should be assayed on a separate plate in series using the method described in the Neutralizing Antibody Assay for HIV-1 in TZM-bl cells each time when screening assays are performed.
- 1.5 Thaw the required number of vials of virus by placing in an ambient temperature water bath. When completely thawed, mix the virus in the tube (**do not vortex**), and dilute the virus in GM to achieve a TCID of approximately 50,000-150,000 RLU equivalents (+/- 15,000 RLU). For pseudoviruses that do not reach 50,000-150,000 RLU, select a dose of virus that gives at least 10 times background RLU but is not toxic to the cells (observed via light microscopy). See Protocol for Preparation and Titration of HIV-1 Env-pseudotyped Viruses for measurement of TCID in TZM-bl cells.

NOTE 8: The RLU equivalents measured in the TCID assay may not necessarily match the RLUs obtained in the virus control of the neutralization plate. This difference is acceptable provided that the virus control is ≥10X the background in cell control wells and the virus control is not toxic to the cells observed by light microscopy.

NOTE 9: Leftover virus may be refrozen in an ultra low temperature freezer and marked with a “1X” on the lid and label of the vial. The “1X” notes that this particular vial has been thawed one time. When using “1X” vials of virus in the TZM-bl assay, the technician must consult the virus database to obtain the optimal virus dilution for viruses that have been thawed one time. No pseudovirus should be used in the

TZM-bl assay if it has been thawed and refrozen more than once.

NOTE 10: For viruses with high dilution (i.e., 1:100 or higher), it is recommended to aliquot and freeze leftover viruses into smaller volumes. The aliquots should be based on the recommended dilution determined from the TCID assay of a 1X thawed virus, aliquot (See Protocol for Preparation and Titration of Env-Pseudotyped Viruses). A “1X” should be written on the cap of the tube and the tube to denote that the virus has been thawed and refrozen once.

1.6 Prepare virus/GM suspension at the recommended dilution as described below:

1.6.1 Virus Calculations:

To calculate the total volume (vol.) of virus/GM mixture needed for the assay, multiply the total number of plates by the volume of virus/GM mixture to be used per plate. Then divide the total volume of virus/GM mixture by the optimal virus dilution to use (based on the TCID assay) to derive the volume of undiluted virus needed. Then subtract the volume of undiluted virus needed from the total volume of virus/GM mixture to derive the volume of GM needed.

Total number of plates X Vol. of virus/GM per plate = Total vol. virus/GM needed

Total vol. virus/GM needed ÷ Optimal virus dilution = Vol. of undiluted virus needed

Total vol. of virus/GM needed – Vol. of undiluted virus needed = Vol. of GM needed

1.7 The virus/GM suspension should be prepared as follows: Add GM and virus and thoroughly mix immediately prior to plating. Dispense 50 µl of the virus/GM suspension to all wells in columns 2-11, rows B to G.

1.8 Cover the plates and incubate for 45 – 90 minutes.

1.7. During the incubation, prepare a suspension of TZM-bl cells at a concentration of 100,000 cells/ml in GM as described below.

1.7.1. Perform Viable Cell Count (See laboratory specific protocol)

1.7.2. Cell Calculations:

To calculate the cell concentration, count the total number of cells in a predetermined number of quadrants in a hemacytometer and obtain the average cells count per quadrant. Multiply this number by the dilution factor to yield the cell concentration, “C₁,” in cells x 10⁴. To calculate the total cell mixture volume, “V₂,” that you need, multiply the number of plates by the total volume of cell mixture needed per plate. The concentration of cells desired is 100,000 cells/ml, “C₂.” Thus, using the equation C₁V₁ = C₂V₂, one can solve for “V₁,” the volume of cells needed.

For example:

Total number of cells counted = 60
Number of quadrants counted = 4
Dilution factor = 10
Number of plates = 1
Cell mixture needed per plate = 10 ml

$60 \text{ cells} \div 4 \text{ quadrants} = 15 \text{ cells/quadrant}$

$15 \text{ cells/quadrant} \times \text{dilution factor of } 10 \times 10,000 \text{ cells/ml} = 1.5 \times 10^6 \text{ cells/ml}$

$1 \text{ plate} \times 10 \text{ ml / plate} = 10 \text{ ml} = V_2$

Optimum final concentration of cells = $1 \times 10^5 \text{ cells/ml} = C_2$

$C_1 V_1 = C_2 V_2$ Therefore: $V_1 = C_2 V_2 \div C_1$

$(1 \times 10^5 \text{ cells/ml} \times 10 \text{ ml}) \div 1.5 \times 10^6 \text{ cells/ml} = 0.67 \text{ ml of cells}$

1.7.3. Addition of DEAE-Dextran to Cells

NOTE 11: The concentrations of DEAE-Dextran shown will vary by batch of DEAE-Dextran. The actual optimal concentration should be determined for each new batch of DEAE-Dextran prepared in accordance with the Protocol for the Determination of Optimal Concentration of DEAE-Dextran.

To calculate the amount of DEAE-Dextran to use, first multiply the optimal concentration of DEAE-Dextran by 0.250ml (the final volume in each well) to get the amount of DEAE-Dextran per well. Multiply the amount of DEAE-Dextran per well by 100 wells/plate (96 wells rounds to 100) to derive the amount of DEAE-Dextran per plate. Divide the amount of DEAE-Dextran needed per plate by the stock concentration of the DEAE-Dextran to yield the volume of DEAE-Dextran stock needed. Multiply this number by the number of plates to yield the total volume of DEAE-Dextran stock needed.

For example:

If the optimal concentration of DEAE-Dextran in the assay is 10 µg/ml and the DEAE-Dextran stock is at 5 mg/ml:

$10 \text{ µg/ml} \times 0.25 \text{ ml (volume in well)} = 2.5 \text{ µg of DEAE-Dextran needed in each well}$

$2.5 \text{ µg} \times 100 \text{ wells/plate} = 250 \text{ µg of DEAE-Dextran needed per plate} = 0.25 \text{ mg of DEAE-Dextran}$

$0.25 \text{ mg of DEAE-Dextran per plate} \div 5 \text{ mg/ml stock concentration} = 0.05 \text{ ml of DEAE-Dextran stock needed per plate}$

To calculate the amount of Growth Medium to add, subtract the total volume of cells

needed and the total volume of DEAE-Dextran stock needed from the total volume of cell mixture needed.

The total volume needed for one plate is 10 ml.

10 ml – 0.67 ml cells – 0.05 ml DEAE-Dextran = 9.28 ml of GM

- 1.8. The GM/cells/DEAE-Dextran suspension should be prepared as follows: Add GM and DEAE-Dextran then mix. Add cells and thoroughly mix the prepared cell suspension immediately prior to plating. Dispense 100 µl of the prepared cell suspension (10,000 cells per well) to each well in columns 1-11, rows B to G. Cells should be added to cell control wells first (on all plates) and then from row B to G.

NOTE 12: The use of DEAE-Dextran is optional. When omitted, the TCID of the virus should be measured in the absence of DEAE-Dextran.

- 1.9. Cover plates and incubate for 44-72 hours if Env-pseudotyped viruses are used. If replication-competent virus is used, the plates should be incubated for 44-50 hours to minimize virus replication.
- 1.10. After incubation, remove plates from the incubator. Plates should not stay out of the incubator longer than one hour before running the luciferase reaction.

NOTE 13: Using a light microscope, examine at least 2 virus control wells for the presence of syncytia. It is important to note the presence of syncytia as too many syncytia indicate cell killing and thus the validity of the assay is compromised. If cell killing is present, the assays should be repeated using a lower dose of the virus. It is important that all wells of the plate containing test sample be checked for the presence of toxicity. Cell toxicity could be erroneously interpreted as neutralization.

- 1.11. Thaw Britelite™ plus or Bright-Glo directly before use in an ambient temperature water bath away from the light. Once thawed, invert tube a few times to mix. Britelite should be used as room temperature.
- 1.12. Remove 150 µl of culture medium from each well, leaving approximately 100 µl.
- 1.13. Dispense 100 µl of Britelite™ plus or Bright-Glo to each well in columns 1-11, in rows B to G.
- 1.14. Incubate away from light at room temperature for 2 minutes (but not longer than 15 minutes) to allow complete cell lysis then mix by pipettor action (at least two strokes) and transfer 150 µl to a corresponding 96-well black plate. Read the plate in a luminometer.

2. Analyzing and printing results

- 2.1. Prior to reading the plates in the luminometer, enter the assay protocol information in the Wallac Software of the luminometer.
- 2.2. Read the plates in a luminometer interfaced to a dedicated computer in the laboratory. Two

data files will be generated from the luminometer for each plate read: an Excel file and a non-modifiable file.

- 2.3. The software program associated with the luminometer automatically saves the raw data in Excel format in a desired location, after each plate is read, using a unique file identification number (ID) for each plate.
- 2.4. Save the original plate data file directly from the Wallac Software as a PDF file or another non-modifiable file. This file should also be saved automatically in a read only folder, for archival purpose.
- 2.5. Analyze print the data using the appropriate Microsoft Excel screening macro (provided by the Central Reference Laboratory).
- 2.6. Select the “Save Report” option to save the report file to a secure server.

NOTE 14: Percent neutralization is determined by calculating the difference in average RLU between test wells containing post-immune sample and test wells containing pre-immune sample from the same individual. The pre-immune and post-immune samples must be assayed on the same assay plate in order as specified.

NOTE 15: For samples where the pre-immune sample is not available (setting as in Appendix C), percent neutralization is determined by calculating the difference in average RLU between test wells and virus control.

- 2.7. Prepare a data packet to provide to the final reviewer and /or PI. The data package should include, at a minimum, the following items:
 - 2.7.1. The data run summary, which must include: i) experiment number, ii) protocol and/or study number, iii) cells used in the assay, iv) length of incubation in hours, v) name, date, lot number, and dilution of the virus stock used, vi) all pertinent sample information and vii) signature of technician who performed the assay.
 - 2.7.2. A copy of the original plate data file from the luminometer (saved as a non-modifiable file) may be kept in electronic form.

NOTE 16: Based upon the PI’s request, a copy of the original plate data (saved as a non-modifiable file) may be kept in electronic form.

3. Pass/Fail Criteria

- 3.1. The average RLU of virus control wells is ≥ 10 times the average RLU of cell control wells.
- 3.2. The percent CV (%CV) between RLU in the virus control wells is $\leq 30\%$.
- 3.3. The percent CV (%CV) between RLU in the cell control wells is $\leq 30\%$.
- 3.4. The percent difference for triplicate wells is $\leq 30\%$ for sample dilutions that yield at least 40% neutralization.

- 3.5. The percent difference for duplicate wells for positive control is acceptable ($\leq 30\%$ for sample dilutions that yield at least 40% neutralization).
- 3.6. Positive Control neutralization curve crosses the 50% neutralization cut-off 0-1 times
- 3.7. The value of the positive control is within a 3-fold of the average of the previous values for that particular control-virus combination.

NOTE 17: A final decision regarding the acceptability of the data will be made by the PI (or his/her Designee).

4. References

- 4.1. Platt, E.J., K. Wehrly, S.E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infection by macrophage tropic isolates of human immunodeficiency virus type 1. *J. Virol.* 72:2855-2864.
- 4.2. Wei, X., J.M. Decker, H. Liu, Z. Zhang, R.B. Arani, J.M. Kilby, M.S. Saag, X. Wu, G.M. Shaw, and J.C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. *Antimicrob. Agents Chemother.* 46:1896-1905.
- 4.3. Sarzotti-Kelsoe, M., R.T. Bailer, E. Turk, C.L. Lin, M. Bilska, K.M. Greene, H. Gao, C.A. Todd, D.A. Ozaki, M.S. Seaman, J.R. Mascola, and DC. Montefiori. 2013. Optimization and Validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. *J. Immunol Methods.* Doi:pii: S0022-1759(13)00359-1.10.1016/j.jim.2013.110.22.

5. Appendix

A: Assay template for screening at a single serum dilution (1 pre and 1 post)

	1	2	3	4	5	6	7	8	9	10	11	12
A	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB
B	CC	VC	S #3 Post	S #3 Post	S #3 Post	S #6 Post	S #6 Post	S #6 Post	S #9 Post	S #9 Post	S #9 Post	MB
C	CC	VC	S #3 Pre	S #3 Pre	S #3 Pre	S #6 Pre	S #6 Pre	S #6 Pre	S #9 Pre	S #9 Pre	S #9 Pre	MB
D	CC	VC	S #2 Post	S #2 Post	S #2 Post	S #5 Post	S #5 Post	S #5 Post	S #8 Post	S #8 Post	S #8 Post	MB
E	CC	VC	S #2 Pre	S #2 Pre	S #2 Pre	S #5 Pre	S #5 Pre	S #5 Pre	S #8 Pre	S #8 Pre	S #8 Pre	MB
F	CC	VC	S #1 Post	S #1 Post	S #1 Post	S #4 Post	S #4 Post	S #4 Post	S #7 Post	S #7 Post	S #7 Post	MB
G	CC	VC	S #1 Pre	S #1 Pre	S #1 Pre	S #4 Pre	S #4 Pre	S #4 Pre	S #7 Pre	S #7 Pre	S #7 Pre	MB
H	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB

CC, Cell control wells (cells only). VC, virus control wells (virus and cells but no serum sample are added here). MB, media blank wells. S #, Sample number

B. Assay template for screening at a single serum dilution (1 pre and 2 post)

	1	2	3	4	5	6	7	8	9	10	11	12
A	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB
B	CC	VC	S #2 Post	S #2 Post	S #2 Post	S #4 Post	S #4 Post	S #4 Post	S #6 Post	S #6 Post	S #6 Post	MB
C	CC	VC	S #2 Post	S #2 Post	S #2 Post	S #4 Post	S #4 Post	S #4 Post	S #6 Post	S #6 Post	S #6 Post	MB
D	CC	VC	S #2 Pre	S #2 Pre	S #2 Pre	S #4 Pre	S #4 Pre	S #4 Pre	S #6 Pre	S #6 Pre	S #6 Pre	MB
E	CC	VC	S #1 Post	S #1 Post	S #1 Post	S #3 Post	S #3 Post	S #3 Post	S #5 Post	S #5 Post	S #5 Post	MB
F	CC	VC	S #1 Post	S #1 Post	S #1 Post	S #3 Post	S #3 Post	S #3 Post	S #5 Post	S #5 Post	S #5 Post	MB
G	CC	VC	S #1 Pre	S #1 Pre	S #1 Pre	S #3 Pre	S #3 Pre	S #3 Pre	S #5 Pre	S #5 Pre	S #5 Pre	MB
H	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB

CC, Cell control wells (cells only). VC, virus control wells (virus and cells but no serum sample are added here). MB, media blank wells. S #, Sample number.

C. Assay template for screening at a single serum dilution (no pre)

	1	2	3	4	5	6	7	8	9	10	11	12
A	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB
B	CC	VC	S# 6	S# 6	S# 6	S# 12	S# 12	S# 12	S# 18	S# 18	S# 18	MB
C	CC	VC	S# 5	S# 5	S# 5	S# 11	S# 11	S# 11	S# 17	S# 17	S# 17	MB
D	CC	VC	S# 4	S# 4	S# 4	S# 10	S# 10	S# 10	S# 16	S# 16	S# 16	MB
E	CC	VC	S# 3	S# 3	S# 3	S# 9	S# 9	S# 9	S# 15	S# 15	S# 15	MB
F	CC	VC	S# 2	S# 2	S# 2	S# 8	S# 8	S# 8	S# 14	S# 14	S# 14	MB
G	CC	VC	S# 1	S# 1	S# 1	S# 7	S# 7	S# 7	S# 13	S# 13	S# 13	MB
H	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB	MB

CC, Cell control wells (cells only). VC, virus control wells (virus and cells but no serum sample are added here). MB, media blank wells. S#, Sample number.

D: Sample Dilution Chart

Screen Dilution	GM Volume (µl)	Sample Volume (µl)
1:5	70	30
1:10	85	15
1:20	93	7.5
1:30	95	5
1:50	97	3